Background Using the GWTG-Stroke database and the Centers for Medicare & Medicaid Service files, we analyzed Medicare patients with acute ischemic stroke.

Slides:



Advertisements
Similar presentations
© 2010, American Heart Association. All rights reserved. Hospital Performance Recognition with the Get with the Guidelines Program and Mortality for Acute.
Advertisements

© 2010, American Heart Association. All rights Association of Hospital Primary Angioplasty Volume in ST-Segment Elevation Myocardial Infarction With Quality.
© 2010, American Heart Association. All rights reserved. Are Quality Improvements Associated with the GWTG-Coronary Artery Disease (GWTG-CAD) Program Sustained.
© 2010, American Heart Association. All rights reserved. A Validated Risk Score for In-hospital Mortality in Patients with Heart Failure from the American.
The Golden Hour and Acute Brain Ischemia: Presenting Features and Lytic Therapy in Over 30,000 Patients Arriving within 60 Minutes of Onset at GWTG-S.
Hernandez et al. JAMA, May 5, 2010 – Vol. 303, No. 17 Relationship Between Early Physician Follow-up and 30-day Readmission Among Medicare Beneficiaries.
1 Costs and Rehabilitation of Stroke Patients: A Retrospective Study of Medicare Beneficiaries Richard D. Zorowitz, MD 1 ; Er Chen, MPP 2 ; Kuo B. Tong,
Current Quality of Cardiovascular Prevention for Million Hearts™ An Analysis of 147,038 Outpatients from The Guideline Advantage ™ Zubin J. Eapen, MD,
Risks of Intracranial Hemorrhage among Patients with Acute Ischemic Stroke Receiving Warfarin and Treated with Intravenous Tissue Plasminogen Activator.
Sumeet Subherwal, Richard G. Bach, Anita Y. Chen, Brian F. Gage, Sunil V. Rao, Tracy Y. Wang, W. Brian Gibler, E. Magnus Ohman, Matthew T. Roe, Eric D.
Connie N. Hess, MD, Bimal R. Shah, MD, MBA, S. Andrew Peng, MS, Laine Thomas, PhD, Matthew T. Roe, MD, MHS, Eric D. Peterson, MD, MPH Relationship of Early.
DISCLOSURE INFORMATION: Target: Stroke is an initiative provided by the American Heart Association/American Stroke Association. The University of California,
DISCLOSURE INFORMATION (relative only): Eric D. Peterson, PI of the AHA GWTG Data Analysis Center; Lee H. Schwamm, Chair of the AHA National Steering Committee.
Kelley M. Anderson, PhD, FNP
Unplanned 30-Day Readmission Risk Among Patients with Acute Myocardial Infarction: a Report from TRANSLATE-ACS Connie N. Hess, MD 1 ; Tracy Y. Wang, MD,
“Influence of Stroke Subtype on Quality of Care in The Get With The Guidelines-Stroke Program” Eric E. Smith, MD, MPH; Li Liang PhD; Adrian F Hernandez,
Trends in the Use of Evidence-Based Treatments for Coronary Artery Disease Among Women and the Elderly Findings From the Get With the Guidelines Quality-
Cohen et al. Circulation. ePub May 17, 2010 Racial and Ethnic Differences in the Treatment of Acute Myocardial Infarction Findings From Get With The Guidelines.
Regional Differences in Quality of Care and Outcomes for the Treatment of Acute Coronary Syndromes: An Analysis from the Get With The Guidelines Program.
The Impact of Intensive Care Unit Structure on Post-operative Outcomes Following Congenital Heart Surgery: Analysis of a Multi-institutional Database Danielle.
The Relationship Between CMS Quality Indicators and Long-term Outcomes Among Hospitalized Heart Failure Patients Mark Patterson, Ph.D., M.P.H. Post-doctoral.
“Influence of age on the management of heart failure: Findings from Get With the Guidelines–Heart Failure (GWTG-HF)” Daniel E. Forman, MD; Christopher.
Are Quality Improvements Associated with the GWTG-Coronary Artery Disease (GWTG-CAD) Program Sustained Over Time? A Longitudinal Comparison of GWTG-CAD.
Use of Hydralazine-Isosorbide Dinitrate combination in African American and Other Race/Ethnic Group Patients with Heart Failure and Reduced Ejection Fraction.
“ Age-Related Differences in Characteristics, Performance Measures, Treatment Trends, and Outcomes in Patients with Ischemic Stroke ” Gregg C. Fonarow,
RACIAL DISPARITIES IN PRESCRIPTION DRUG UTILIZATION AN ANALYSIS OF BETA-BLOCKER AND STATIN USE FOLLOWING HOSPITALIZATION FOR ACUTE MYOCARDIAL INFARCTION.
Quality of Care and In-Hospital Outcomes in Patients With Coronary Heart Disease in Rural and Urban Hospitals (from Get With the Guidelines– Coronary.
“Hospital Performance Recognition with the Get with the Guidelines Program and Mortality for Acute Myocardial Infarction and Heart Failure Paul A Heidenreich,
Surveillance of Heart Diseases and Stroke Using Centers for Medicare and Medicaid (CMS) Data: A Researcher’s Perspective Judith H. Lichtman, PhD MPH Associate.
Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention JA Rassen, MA Mittleman, RJ Glynn, A.
Quality of Care and Outcomes in Patients with Diabetes Hospitalized with Ischemic Stroke Findings From Get With The Guidelines-Stroke Reeves MJ; Vaidya.
Readmission for Stroke and Quality of Care among Patients Hospitalized with Transient Ischemic Attack (TIA): Findings from Get With The Guidelines (GWTG)-Stroke.
Clinical Effectiveness of Implantable Cardioverter-Defibrillators Among Medicare Beneficiaries With Heart Failure Adrian F. Hernandez, MD, MHS; Gregg.
Patients with HF have increased risk for thrombotic events. However, the net clinical benefit of anticoagulation in a HF population in sinus rhythm has.
Schwamm et al. Circulation epub April 6Schwamm et al. Race/Ethnicity, Quality of Care, and Outcomes in Ischemic Stroke Lee H. Schwamm, MD; Mathew.
Around-the-Clock Primary Angioplasty: A Process of Care Analysis Comparing Off-Hours and Normal Hours Treatment of Acute STEMI R Leung, D Lundberg, D Galbraith,
Patterns of red blood cell transfusion use and outcomes in patients undergoing percutaneous coronary intervention in contemporary clinical practice: Insights.
Complete Recovery of Renal Function After Acute Kidney Injury is Associated with Long-Term All-Cause Mortality In a Large Managed Care Organization Jennifer.
Predictors of Cardiac Rehabilitation Referral in Coronary Artery Disease Patients: Results From the AHA’s Get With the Guidelines Program Todd M. Brown,
1 Statin treatment is associated with improved prognosis in patients with AF-related stroke G. Ntaios, V. Papavasileiou, K.Makaritsis, A.Karagiannaki,
” “The Dissociation Between Door-to- Balloon Time Improvement and Improvements in Other Acute Myocardial Infarction Care Processes and Patient Outcomes”
Do Heart Failure Disease Management Programs Make Financial Sense Under a Bundled Payment System? Zubin J. Eapen, Shelby D. Reed, Lesley H. Curtis, Adrian.
Influence of Comorbid Depression and Antidepressant Treatment on Mortality for Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease by SSDI-eligibility.
Stroke The overall age-adjusted mortality rate (AAMR) for stroke in Texas declined from 66.3 per 100,000 in 1999 to 52.1 per 100,000 in The decrease.
Can pharmacists improve outcomes in hypertensive patients? Sookaneknun P (1), Richards RME (2), Sanguansermsri J(1), Teerasut C (3) : (1)Faculty of Pharmacy,
Background Current guideline recommend an early invasive strategy for NSTEMI patients (Class IIA). However, 67% US hospitals have no catheterization capability.
US Department of Veterans Affairs Hip Fractures in VA/Medicare-Eligible Veterans: Mortality and Costs Elizabeth Bass, PhD, 1 Dustin D. French, PhD, 1 Douglas.
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
THE URBAN INSTITUTE Examining Long-Term Care Episodes and Care History for Medicare Beneficiaries: A Longitudinal Analysis of Elderly Individuals with.
PATIENT-CENTERED RESEARCH INTO OUTCOMES STROKE PATIENTS PREFER AND EFFECTIVENESS RESEARCH.
A Comparison of Sevelamer and Calcium-Based Phosphate Binders on Mortality, Hospitalization, and Morbidity in Hemodialysis: A Secondary Analysis of the.
Adverse Outcomes After Hospitalization and Delirium in Persons with Alzheimer Disease Charles Wang, PharmD Candidate.
The Association between blood glucose and length of hospital stay due to Acute COPD exacerbation Yusuf Kasirye, Melissa Simpson, Naren Epperla, Steven.
The Impact of For-Profit Hospital Status on the Care and Outcomes of Patients with NSTEMI: Results From CRUSADE Bimal R. Shah, MD, Seth W. Glickman, MD,
Characteristics, Performance Measures, and In-Hospital Outcomes of the First One Million Stroke and Transient Ischemic Attack Admissions in Get With The.
Trends in the Quality of Care of Patients with Acute Myocardial Infarction: The National Registry of Myocardial Infarction from 1990 to 2006 Bimal R. Shah,
Teaching Intensity, Race and Surgical Outcomes Jeffrey H. Silber The University of Pennsylvania The Children’s Hospital of Philadelphia.
Impact of Prior Myocardial Infarction Among Patients with Acute Myocardial Infarction Treated in Contemporary Practice: A Report from the ACTION Registry.
1 Statistical Review of the Observational Studies of Aprotinin Safety Part II: The i3 Drug Safety Study CRDAC and DSaRM Meeting September 12, 2007 P. Chris.
What is the outcome of Door-to-needle Time within 60minutes for acute ischemic stroke patients treat with t-PA? Chi-Ching Chen 1, Hui-Fen Huang 1, Yu-Ling.
Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.
Antiplatelet Therapy Use after Discharge among Acute Myocardial Infarction Patients with In-hospital Bleeding Tracy Y. Wang, MD, MHS, Lan Xiao, PhD, Karen.
Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-term Risk of Mortality and End-Stage Renal Disease.
R1 강민혜 / prof. 전숙. Introduction Patients with type 2 diabetes have a greatly increased risk of cardiovascular events. The morbidity and mortality related.
Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: Readmissions After Carotid Artery Revascularization.
Landon Marshall, Pharm. D. , Matt Hill, Pharm. D. , Jim Wilson, Pharm
Baseline characteristics of HPS participants by prior diabetes
Age and Gender Differences in Quality of Care and Outcomes for Patients with ST- segment Elevation Myocardial Infarction  Sripal Bangalore, MD, MHA, Gregg.
Antiplatelet Therapy Use after Discharge among Acute Myocardial Infarction Patients with In-hospital Bleeding Tracy Y. Wang, MD, MHS, Lan Xiao, PhD, Karen.
Atlantic Cardiovascular Patient Outcomes Research Team
Presentation transcript:

Background Using the GWTG-Stroke database and the Centers for Medicare & Medicaid Service files, we analyzed Medicare patients with acute ischemic stroke admitted to GWTG-Stroke hospitals between April 1, 2003 and December 12, We found concurrent controls at non-GWTG-Stroke hospitals using a matching process based upon average annual ischemic stroke volume, calendar time, hospital teaching status, and hospital region. We defined 4 separate time periods of interest: PRE (18 mos-16 mos prior to joining GWTG-Stroke) RUN-UP (6 mos-1 day prior to GWTG-Stroke) EARLY (day 0-6 months after GWTG-Stroke) SUSTAINED (6 mos-18 mos after GWTG-Stroke). We further combined time periods: PRE+RUN-UP = BEFORE EARLY+SUSTAINED = AFTER. Using site-level Kaplan-Meier estimates and Kruskal-Wallis tests, we analyzed the GWTG-Stroke sites and the non-GWTG-Stroke sites separately in each of the four time periods for the following clinical outcomes: length of stay, discharge home, 30 day mortality, 1 year mortality, 30 day all cause rehospitalization, 30 day stroke rehospitalization, 30 day cardiovascular rehospitalization, 1 year all cause mortality, 1 year stroke mortality, and 1 year cardiovascular mortality. We also analyzed ischemic stroke patients enrolled during the PRE period in both GWTG-Stroke and non-GWTG-Stroke hospitals utilizing a stratified/conditional Cox proportional hazard model with the pair number (1-366) as the stratum; we also analyzed the data using the pre-period hospital level risk rate as an offset in each model. We performed risk adjusted mortality (30 day and 1 year) and discharge to home rates for what we determined to be the most common baseline patient (female, 80 years, white, no medical history, and average-sized hospital). *Outcome Sciences, Inc. is the data collection coordination center for the American Heart Association/American Stroke Association Get With The Guidelines® programs Results Conclusions Limitations P< Stroke is a devastating disease, affecting more than 795,000 people in the U.S. each year. The Get With The Guidelines-Stroke (GWTG-Stroke) program was developed by the American Heart Association (AHA) as a quality improvement program for hospitals to improve stroke care infrastructure utilizing a multidisciplinary team approach, and offering data collection, decision support, and data feedback. Participation in the GWTG-Stroke program has also been associated with increased adherence to quality performance measures and increased number of patients with stroke treated over time. Although improvement of these quality of care measures, such as early antithrombotics and smoking cessation, have been seen in patients at GWTG-Stroke hospitals, longer term clinical outcomes, such as mortality, discharge to home, or rehospitalization has not been described. Get With The Guidelines-Stroke Program Participation and Clinical Outcomes for Medicare Beneficiaries Sarah Song MD, MPH 1, Gregg C. Fonarow MD 2, Wendy Pan PhD 3, DaiWai M Olson PhD, RN 4, Adrian F. Hernandez MD, MS 5, Eric D. Peterson MD, MPH 5, Mathew J. Reeves PhD 6, Eric E. Smith MD, MPH 7, Lee H. Schwamm MD 8, Jeffrey L. Saver MD 9 1 Department of Neurology, Rush University Medical Center; 2 Department of Cardiology, University of California-Los Angeles; 3 Department of Biostatistics & Bioinformatics, Duke University; 4 Department of Neurology, Duke University; 5 Department of Cardiology, Duke University; 6Department of Epidemiology and Biostatistics, Michigan State University; 7 Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary; 8 Department of Neurology, Massachusetts General Hospital; 9 Department of Neurology, University of California-Los Angeles Author Disclosure Information: S. Song: Research Grant; Modest; American Heart Association/Pharmaceutical Roundtable – Spina Outcomes Research Center. G.C. Fonarow: None. W. Pan: None. D.M. Olson: None. A.F. Hernandez: None. E.D. Peterson: Research Grant; Modest; BMS/Sanofi, J&J, Lilly, PI of AHA Data Coordinating Center (for GWTG). M.J. Reeves: None. E.E. Smith: None. L.H. Schwamm: Consultant/Advisory Board; Significant; Consultant Stroke Systems MA DPH. Other; Modest; Chair, AHA GWTG (unpaid). J.L. Saver: None. In this study, we found that patients hospitalized with acute ischemic stroke at GWTG-Stroke hospitals had greater improvement of clinical outcomes over time, than similar non-GWTG-Stroke hospitals. GWTG-Stroke hospitals exhibited reduced proportional 30 day and 1 year mortality, and had more discharges home. Encouragingly, both linked and unlinked hospitals improved their stroke outcome over time. The GWTG-Stroke program continues to show benefits of hospital participation in clinical outcomes. Participation in GWTG-Stroke was voluntary and the control hospitals while concurrent were not based on randomization. Despite our best efforts, matching GWTG-Stroke hospitals with non- GWTG-Stroke hospitals was not perfect, and the matched pairs had significant differences on most outcomes in the PRE period Residual measured and unmeasured confounding may have occurred There was a small amount of missing data which happened most frequently in the SUSTAINED period, due to end of CMS data reporting Acknowledgements NIH/NIA RCMAR/CHIME GWTG-Stroke is provided by the American Heart Association/American Stroke Association and is currently supported, in part, by a charitable contribution from Janssen Pharmaceutical Companies of Johnson & Johnson. GWTG-Stroke has been funded in the past through support from Boeringher-Ingelheim, Merck, Bristol- Myers Squib/Sanofi Pharmceutical Partnership, and the AHA Pharmaceutical Roundtable. A total of 173,985 patients, with 88,584 patients at 366 GWTG-Stroke sites, and 85,401 patients at 366 matched non-GWTG-Stroke sites included in the analysis.Patient characteristics were similar in PRE and SUSTAINED periods. In GWTG-Stroke hospitals between the PRE and the SUSTAINED periods, there was significantly Improved median 30-day mortality of 15.08% to 14.63% Improved median 1-year mortality of 28.25% to 27.59% Decreased median 30-day stroke rehospitalization of 4.36% to 4.05% Increased median 30-day cardiovascular disease rehospitalization of 3.03% to 3.08% In non-GWTG-Stroke hospitals between the PRE and the SUSTAINED periods, there was significantly: Decreased median 30-day stroke rehospitalization of 4.55% to 4.27% Increased median 30-day cardiovascular rehospitalization of 2.65% to 2.94% Univariate analysis of the SUSTAINED period found that clinical outcomes were similar, except that GWTG- Stroke hospitals had decreased stroke/TIA rehospitalizations at 1 year than non-GWTG-Stroke hospitals: 15.2% compared to 16.4% (p<0.0002) GWTG-Stroke hospitals had statistically significantly improved outcomes than non-GWTG-Stroke hospitals during the PRE period for the following: discharge home, 30 and 1 year mortality, 30 day cardiovascular rehospitalization, and 1 year stroke rehospitalization Patient Characteristics Comparing Clinical Outcomes at GWTG-Stroke Hospitals to Non-GWTG-Stroke Hospitals Hospital Characteristics Overall PRE period (N = 58,830) GWTG-Stroke hospital (N = 29,217) Non-GWTG- Stroke hospital (N = 29,613) P-value (Wilcoxon two-sample / Chi- square) Patient age (mean) years (SD 7.86) years (SD 7.86) years (SD 7.85) P < Female %59.98% %P < White %84.16%85.45%82.89%P < Comorbidities Hypertension77.90%77.75%78.06%P = Acute myocardial infarction 10.44%10.48%10.39%P = Stroke8.83%8.59%9.06%P = Coronary artery disease 33.90%33.72%34.08%P = Diabetes29.24%28.31%30.16%P < Pneumonia8.55%8.43%8.67%P = Renal disease7.24%7.06%7.42%P = COPD19.17%18.63%19.70%P = Dementia4.58%4.24%4.92%P < Carotid stenosis9.16%9.38%8.95%P = Peripheral vascular disease 9.77%9.73%9.82%P = Overall POST period (N = 57,056) GWTG-Stroke hospital (N = 30,058) Non-GWTG- Stroke hospital (N = 26,998) P-value (Wilcoxon two-sample / Chi- square) Patient age (mean)79.65 (SD 7.99)79.68 (7.97)79.63 (SD 8.02)P<0.339 Female %59.35%58.82%59.95%P<0.006 White %84.38%85.36%83.29%P < Comorbidities Hypertension79.18%79.04%79.34%P = Acute myocardial infarction 10.44%10.89%9.95%P= Stroke8.98%9.82%8.04%P< Coronary artery disease 34.07%34.59%33.49%P=0.006 Diabetes29.75%29.39%30.16%P=0.044 Pneumonia8.96%8.73%9.21%P=0.046 Renal disease13.34%13.22%13.49%P=0.347 COPD19.95%19.86%20.05%P=0.567 Dementia3.88%3.85%3.92%P=0.669 Carotid stenosis11.29%13.57%8.76%P< The majority of hospitals analyzed were from the South, followed by the Northeast; 2.73% of hospitals were in rural areas. The overall mean number of beds per hospital was 278.5, and the mean number of ischemic stroke discharges per hospital was Clinical Outcomes for GWTG-Stroke Hospitals vs. Non-GWTG-Stroke Hospitals during the PRE period Unadjusted AnalysisAdjusted Analysis Hazard Ratio Confidence Interval Prob ChiSq Hazard Ratio Confidence Interval Prob ChiSq Discharge Home Death in 30 day from admission <.0001 Death in 1 year from discharge < <.0001 Any Rehospitalization in 30 days after Discharge Stroke Rehospitalization in 30 days after Discharge CVD Rehospitalization in 30 days after Discharge Any Rehospitalization in 1 year after Discharge Stroke Rehospitalization in 1 year after Discharge CVD Rehospitalization in 1 year after Discharge Ratio of Adjusted Hazard Ratios at GWTG- Stroke Hospitals vs. Changes at Non-GWTG- Stroke Hospitals in RUN-UP, EARLY and SUSTAINED periods compared with PRE period RUN-UP vs. PREEARLY vs. PRESUSTAINED vs. PRE Hazard Ratio Confidence Interval Prob ChiSq Hazard Ratio Confidence Interval Prob ChiSq Hazard Ratio Confidence Interval Prob ChiSq Discharge Home < < <.0001 Death in 30 day from admission Death in 1 year from discharge < <.0001 Any Rehospitalization in 30 days after Discharge Stroke Rehospitalization in 30 days after Discharge CVD Rehospitalization in 30 days after Discharge Any Rehospitalization in 1 year after Discharge Stroke Rehospitalization in 1 year after Discharge CVD Rehospitalization in 1 year after Discharge By using the PRE period hospital level risk rate as an offset in each model, GWTG-Stroke hospitals had comparatively: Increased rates of discharge home in the earliest time comparison (PRE vs. RUN-UP) Decreased 30 day and 1 year mortality in both EARLY and SUSTAINED vs. PRE periods Ratio of Adjusted HRs at GWTG-Stroke Hospitals vs. Changes at Non-GWTG-Stroke Hospitals: AFTER vs. BEFORE Ratio of HRs Confidence Interval Prob ChiSq Discharge Home <.0001 Death in 30 day from admission Death in 1 year from discharge Any Rehospitalization in 30 days after Discharge Stroke Rehospitalization in 30 days after Discharge CVD Rehospitalization in 30 days after Discharge Any Rehospitalization in 1 year after Discharge Stroke Rehospitalization in 1 year after Discharge CVD Rehospitalization in 1 year after Discharge When time periods were combined into BEFORE and AFTER periods, GWTG- Stroke hospitals had greater improvement over time in: Discharges to home Mortality at 1 year The Most Common Baseline Stroke Patient GWTG-StrokeNon-GWTG-Stroke Time Period Est. RateStd. Err.Est. RateStd. Err. Risk adjusted 30-day Mortality PRE 16.77%1.66%17.76%2.03% RUN-UP 16.36%2.40%15.60%2.27% EARLY 14.42%2.06%16.16%2.64% SUSTAINED 14.71%1.50%15.39%1.90% BEFORE (PRE+RUN-UP) 16.64%1.37%16.25%1.53% AFTER (EARLY+SUSTAINED) 14.61%1.21%15.76%1.55% Risk adjusted 1-year Mortality PRE 27.83%1.71%28.02%2.31% RUN-UP 26.97%2.58%28.62%3.27% EARLY 24.69%2.37%24.49%2.65% SUSTAINED 23.36%1.62%26.92%2.23% BEFORE (PRE+RUN-UP) 27.27%1.43%28.14%1.88% AFTER (EARLY+SUSTAINED) 23.84%1.34%25.40%1.72% Risk adjusted discharge to home rate PRE 24.76%1.35%26.57%1.50% RUN-UP 25.51%1.97%26.01%2.01% EARLY 25.38%1.78%25.62%2.01% SUSTAINED 25.77%1.31%26.41%1.52% BEFORE (PRE+RUN-UP) 25.03%1.11%26.44%1.20% AFTER (EARLY+SUSTAINED) 25.68%1.06%26.18%1.21% We analyzed risk adjusted mortality values and rates of discharge to home for what we deemed to be our most common baseline patient We found that the risk adjusted 30 day mortality rate decreased for GWTG- Stroke patients from 16.77% in the PRE period to 14.71% in the SUSTAINED period; comparatively, non-GWTG-Stroke patients had an improvement of mortality of 17.76% to 15.39% over the same periods. There was a substantially greater degree of improvement in 30 day mortality when looking at BEFORE and AFTER rates, with GWTG-Stroke hospitals offering an improvement of 16.64% to 14.61%, compared to 16.25% to 15.76%. For1 year mortality, BEFORE and AFTER rates revealed greater improvement in the GWTG-Stroke group, with BEFORE at 27.27%, and AFTER at 23.84%; this was in comparison to non-GWTG-Stroke hospitals, who improved from 28.14% in the BEFORE period to 25.40% in the AFTER period. Methods